Skip to content
Clinical Trials – home
Not yet recruitingRare disease

Phase 2/3 study of bomedemstat versus drug combination to evaluate safety and efficacy in polycythemia vera patients not responding to or intolerant of hydroxyurea

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on polycythemia vera, a rare blood condition where the bone marrow makes too many red blood cells, leading to thickened blood and an increased risk of clots. Participants who have not responded well to or cannot tolerate the standard medicine hydroxyurea may receive the investigational oral capsule called bomedemstat (code name MK-3543) or may continue with the best available therapy, which can include drugs such as ropeginterferon alfa-2b or ruxolitinib.

The purpose of the study is to compare how well the new drug works against the standard options in controlling blood counts and disease symptoms. Participants are randomly assigned to receive either the study drug or the chosen standard therapy, take the medication for several months, and attend regular clinic visits where blood tests and questionnaires are completed to monitor health.

Key outcomes include the clinicohematologic response, which means improvement in blood counts and disease signs, as well as safety measures such as any unwanted side effects, called adverse events, and the need for procedures like phlebotomy, which is the removal of blood to keep levels in a safe range. The study tracks these factors over time to see how long the benefits last and whether the disease progresses.

The research process

The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment Confirmation

    After joining the study, you receive confirmation that you meet all eligibility criteria and are officially enrolled.

    Your participation is recorded, and you are assigned a unique study identification number.

  2. Step 2

    Randomization to Treatment Group

    You are randomly placed into one of two groups: the bomedemstat group or the best available therapy (BAT) group.

    The assignment is done by a computer system to ensure fairness.

  3. Step 3

    Baseline Assessments

    Before starting any medication, you undergo a series of tests to document your health status.

    These include blood counts, physical examination, and questionnaires that measure symptoms of polycythemia vera.

  4. Step 4

    Start of Study Medication

    If you are assigned to the bomedemstat arm, you begin taking hard capsules that contain the active substance bomedemstat. The dose is specified in the study protocol as a percentage volume/volume preparation and is taken as directed by the study team.

    If you are assigned to the BAT arm, you receive one of the approved comparators:

    Ropeginterferon alfa-2b: a subcutaneous injection of 500 µg administered according to the schedule defined in the protocol.

    Ruxolitinib: an oral tablet of 50 mg taken once daily as instructed.

  5. Step 5

    Regular Monitoring Visits

    You attend scheduled clinic visits throughout the trial to monitor safety and effectiveness.

    During each visit, blood samples are drawn, side effects are reviewed, and symptom questionnaires are completed.

    The study team may adjust the dose of the medication if safety concerns arise.

  6. Step 6

    Assessment of Clinicohematologic Response

    At predefined intervals, typically after 24 weeks of treatment, the study evaluates the clinicohematologic response (CHR) to determine how well the disease is controlled.

    If the response is sustained, additional assessments may continue to measure the duration of response.

  7. Step 7

    Management of Adverse Events

    If you experience any adverse events (unwanted side effects), the study team records them and decides whether a dose change or temporary interruption of the medication is needed.

    In some cases, severe adverse events may require discontinuation of the study treatment.

  8. Step 8

    End‑of‑Treatment Evaluation

    When the treatment period ends, you undergo a final set of assessments similar to the baseline visit.

    These evaluations determine the overall outcome of the trial for you, including disease response, any lasting side effects, and quality‑of‑life measures.

  9. Step 9

    Study Completion

    After the final evaluation, your participation in the trial concludes.

    You receive a summary of the study results related to your involvement, and the study team provides guidance on any further care that may be needed.

Who can join the trial?

10 criteria

  • Has a confirmed diagnosis of Polycythemia vera made by a doctor using the World Health Organization (WHO) guidelines for this condition.
  • Can swallow pills and is able to follow the at‑home instructions for taking the study drug.
  • Has stopped any previous cytoreductive therapy (treatment that lowers blood cell counts) for the time period required by the study.
  • Has already tried at least one other cytoreductive therapy that did not successfully lower the hematocrit (the percentage of red blood cells in the blood).
  • Has shown an inadequate response, resistance, or intolerance to the medicine hydroxyurea according to the study’s rules.
  • Shows no sign of an enlarged spleen (splenomegaly) and has no related symptoms such as feeling full quickly (early satiety), discomfort in the upper left abdomen, or spleen pain.
  • Has a bone‑marrow scarring score of Grade 0 or Grade 1, meaning little or mild scarring, as measured by the European Consensus Criteria for Myelofibrosis.
  • If living with HIV, the virus must be well controlled while taking regular antiretroviral therapy (ART).
  • If testing positive for Hepatitis B surface antigen (HBsAg), you must have been on Hepatitis B antiviral medication for at least 4 weeks and have an undetectable (very low) Hepatitis B viral load.
  • If you have a history of Hepatitis C Virus (HCV) infection, you are eligible only if the HCV viral load is undetectable.

Who cannot join the trial?

7 criteria

  • You have a past or current stomach or intestinal problem that could stop the medicine from being absorbed; gastrointestinal (GI) function means how your stomach and intestines work to take in food and medicines.
  • Tests show you might have a higher chance of bleeding; bleeding risk means you could bleed more easily than usual.
  • You have had cancer before, unless you finished treatment that could cure it and have been cancer‑free for at least two years; malignancy is another word for cancer.
  • You are infected with HIV and have ever had Kaposi’s sarcoma (a type of skin and organ cancer) or Multicentric Castleman’s Disease (a rare disorder that causes enlarged lymph nodes).
  • You are currently taking medicines that treat cancer; anticancer therapy means any treatment used to fight cancer.
  • You have an active infection that needs medication that works throughout your whole body; systemic therapy means treatment that affects the entire body.
  • You had a major operation within the last four weeks before the first dose, or you have not fully recovered from the effects of that operation; major surgical procedure refers to a big operation that requires significant recovery time.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • bomedemstat

    is an experimental oral capsule being tested as a new treatment for polycythemia vera. In this study it is given to participants who have not responded well to or cannot tolerate the standard drug hydroxyurea. Researchers are looking to see if bomedemstat can safely lower the number of red blood cells and improve blood counts compared with other available therapies.

  • ropeginterferon alfa-2b

    is a medication that is injected under the skin. It belongs to a class of drugs called interferons, which help the immune system control abnormal blood cell production. In this trial it is used as an active comparator, meaning it serves as a known treatment against which the new drug bomedemstat is compared.

  • ruxolitinib

    is an oral tablet that blocks specific enzymes (JAK1 and JAK2) involved in signaling pathways that cause excess blood cell growth. It is also used as an active comparator in the study, providing another established option for treating polycythemia vera so researchers can evaluate how bomedemstat performs relative to existing therapies.

What is already known about the treatment

  • Bomedemstat

    This medication is taken by mouth as a hard capsule. It is still experimental and is being studied in clinical trials, not yet approved for general use. It is being tested for the treatment of polycythemia vera, a disease with too many red blood cells. It works by blocking the LSD1 enzyme, which helps reduce the abnormal growth of blood cells, and is classified as an LSD1 inhibitor (epigenetic modulator).

  • Ropeginterferon alfa-2b

    This drug is given as a subcutaneous injection, usually a small dose under the skin. It is approved in several countries for polycythemia vera and related blood disorders. It helps control the disease by acting like a natural interferon, signaling the body to lower the production of excess blood cells. It belongs to the class of pegylated interferons, which are immune‑modulating agents.

  • Ruxolitinib

    This medication is taken orally as a tablet, often at a dose of 50 mg. It is an approved treatment for polycythemia vera and related conditions. It reduces blood cell overproduction by blocking the JAK1 and JAK2 enzymes that send growth signals to blood cells. It is classified as a JAK inhibitor.

Investigated diseases

Polycythemia vera - Polycythemia vera is a chronic blood disorder in which the bone marrow produces an excess of red blood cells, often accompanied by higher numbers of white blood cells and platelets. This overproduction makes the blood thicker than normal, which can slow its flow through small vessels. Over time, the condition may cause the spleen to enlarge as it works harder to filter the excess cells. The increased cell count can gradually worsen, leading to more noticeable symptoms such as fatigue, headaches, and a feeling of fullness. In some individuals, the disease can evolve, showing changes in the bone marrow structure and cell behavior.
Trial detailsLast updated 19 Nov 2026
Age18+ yearsPhasePhase IVTrial ID2026-525630-38-00Protocol codeMK-3543-025Estimated enrolment70 patientsSponsorMerck Sharp & Dohme LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.